高流量间歇性血液透析成人患者静脉万古霉素群体药代动力学模型的外部评估
该研究在加拿大魁北克两个医疗中心回顾性收集274例接受高流量间歇性血液透析成人患者的2386个万古霉素浓度,对已发表的4个群体药代动力学模型进行外部评估;所有模型总体预测性能不佳,Bae等模型表现最佳,中位预测误差16.25%、中位绝对预测误差34.66%。
要点
- 高流量间歇性血液透析患者中,4个已发表万古霉素群体药代动力学模型总体预测性能均不佳。
- Bae等模型中位预测误差16.25%、中位绝对预测误差34.66%,为评估模型中最佳。
- 透析期间与透析间期采集样本的万古霉素浓度预测性能存在差异。
核心结论
- 所有评估的万古霉素群体药代动力学模型在高流量间歇性血液透析成人患者中总体预测性能不佳。
研究设计与样本
- 通过PubMed和EMBASE文献综述筛选已发表的万古霉素群体药代动力学模型。
- 从加拿大魁北克2个医疗中心回顾性收集274例患者、476个抗生素疗程的2386个万古霉素浓度。
- 将选定模型在NONMEM(v7.5)中实现,采用预测和基于模拟的诊断评估预测性能。
主要发现
- 4个万古霉素群体药代动力学模型被纳入外部评估。
- 没有模型显示总体令人满意或临床可接受的预测性能。
- Bae等模型表现最佳,中位预测误差为16.25%,中位绝对预测误差为34.66%。
- 透析期间与透析间期采集样本的万古霉素浓度预测性能不同。
局限性
- 所有评估模型总体预测性能不佳,需通过现有模型参数重估计或开发新模型来充分描述该高流量间歇性血液透析患者队列的万古霉素药代动力学。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Patients undergoing haemodialysis (HD) are at greater risk of methicillin-resistant Staphylococcus aureus infections requiring intravenous vancomycin. Close vancomycin therapeutic drug monitoring is warranted in HD patients as renal clearance is the primary elimination pathway. Clinically, population pharmacokinetics (popPK) model-informed dosing is commonly used. This study aimed to perform an external evaluation of published vancomycin popPK models developed for adults undergoing high-flux intermittent HD, and to create a dosing nomogram derived from the model that performed best. METHODS: A literature review was conducted through PubMed and EMBASE to identify relevant popPK models. an external dataset was collected retrospectively from patients of 2 healthcare centres in Quebec, Canada. Selected models were implemented in NONMEM (v7.5; ICON Development Solutions). Predictive performance was assessed through prediction and simulation-based diagnostics. RESULTS: In total, 2386 vancomycin concentrations were collected from 274 patients and 476 antibiotic courses. Four vancomycin popPK models were selected for evaluation. None of the models demonstrated overall satisfactory or clinically acceptable predictive performance. Nonetheless, Bae et al.'s model performed best with a median prediction error of 16.25% and median absolute prediction error of 34.66%. Different predictive performance was also observed for vancomycin concentrations from samples collected during and between HD sessions. CONCLUSION: All evaluated models presented poor overall predictive performance. Further studies are required, through existing popPK model parameter re-estimation or new model development, to adequately describe vancomycin pharmacokinetics for our high-flux intermittent HD patient cohort.
引用
- Ji C, Garcia J, Sabuga AJ, et al. External evaluation of intravenous vancomycin population pharmacokinetic models in adults receiving high-flux intermittent haemodialysis. Br J Clin Pharmacol. 2024. PMID: 39520248. doi:10.1111/bcp.16334
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。